Hormone Replacement Therapy Market Overview

“The Hormone Replacement Therapy Market is estimated to increase at a CAGR of 6.45% from $ 21.52 billion in 2023 to $ 33.56 billion by 2030.”

Hormone replacement therapy (HRT) is used to treat symptoms of female menopause, such as hot flashes, vaginal shrinkage, rapid skin aging, vaginal dryness, reduced muscle mass, sexual dysfunction, and bone loss or osteoporosis, which are primarily linked to decreased sex hormone levels postmenopause.

Hormones commonly used in hormone replacement therapy (HRT) are oestrogens and progestogens. Progesterone is produced artificially for menopausal hormone treatment, while progestogen is added to oestrogen regimens to reduce endometrial cancer risk. Both classes of hormones can help with symptoms, but unopposed oestrogen medication increases cancer risk and encourages endometrial hyperplasia, while progestogen lowers this risk. HRT is accessible through various channels.

Hormone replacement therapy demand is expected to rise from 2023 to 2030 due to factors such as the growing geriatric population, increased menopausal women, favorable reimbursement policies, novel medications, and the popularity of tailored therapies for chronic diseases. By the trial period's end, bio-identical hormone replacement therapy is expected to be highly popular.

NHS England introduced a new HRT prescription prepayment certificate in April 2023, expected to benefit approximately 400,000 women nationwide.

What Are the Benefits for Startups in the Global HRT Market?

Menopause, a taboo topic, presents a significant opportunity for hormone replacement therapy providers. With an aging population and increasing women entering menopause, the lack of effective care is a concern. Companies offering hormone replacement treatment are focusing on revenue to support R&D and product innovation.

>>>Download Sample Report Now: https://marketreportservice.com/request-sample/hormone-replacement-therapy-market-54491

Hormone Replacement Therapy Market Segment Analysis

The hormone replacement market is divided into oestrogen and combined treatment, growth, thyroid, and testosterone therapy categories. Oestrogen and combined hormone replacement therapy have dominated market expansion due to increased acceptance, availability, and awareness of menopausal symptoms. Theramex announced in September 2021 that Bijuva/Bijuve, the first body identical combination hormone therapy medication for post-menopausal women in Europe and the U.K., will be available, fueling the segment's growth.

Pill and tablet form of HRT medicines are widely used due to patient desire, ease of administration, availability, affordability, and improved patient compliance. Parenteral administration methods include Humatrope HumatroPen, Genotropin Mixer Pen, and Norditropin FlexPro Pen.

The Menopause segment is expected to experience a healthy CAGR over the forecast period, as it marks the end of a woman's menstrual cycle after 12 months without a cycle. Typically diagnosed between 40 and 50, this biological process can be improved by hormone replacement treatment, which helps maintain oestrogen levels in older women, thereby enhancing their quality of life.

Market Dynamics

Drivers

• A growing elderly population
• Growing understanding of difficulties related to menopause
• New medicine delivery methods are being developed more often to address hormone imbalance problems.
• increases in the frequency of hormonal diseases

Restraints

• The high price of hormone replacement treatment
• Hormone replacement treatment side effects

Competitive Landscape of the Hormone Replacement Therapy Market Analysis

• Novo Nordisk A/S
• Bayer AG
• Endo International Plc
• Janssen NV
• Mithra Pharmaceuticals
• Novartis AG
• Pfizer Inc.
• Allergen Plc
• Merck KGaA
• Teva Pharmaceuticals
• Mylan N.V.

New Developments in Hormone Replacement Therapy Market

April 28 2023 FDA approves once-weekly Sogroya® for the treatment of children living with growth hormone deficiency

Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg for the treatment of children aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone.1 With this new indication, Sogroya® becomes the first and only once-weekly growth hormone (GH) treatment for both children and adults.

October 17, 2022 Bayer expands development program for elinzanetant with Phase III study in breast cancer patients with vasomotor symptoms caused by endocrine therapy

Bayer, a global leader in women’s healthcare, announced today that it expands the Phase III clinical development program OASIS by initiating OASIS 4 – a Phase III study in breast cancer patients and women with high risk for breast cancer with vasomotor symptoms caused by endocrine therapy.

In February 2022, MHLW of Japan approved NGENLA of Pfizer, Inc. and OPKO which is a long-lasting treatment for pediatric growth hormone deficiency. This strategic initiative helps the companies to expand their customer base in different geography and boost their revenue.

In March 2022, Vira Health, a United Kingdom-based company focused on providing personalized digital therapeutics for menopausal women, announced that it has raised US$ 12 million from Octopus Ventures and participation from other investors as well. The company has plans of using the raised capital to advance its personalized menopause support offerings for women.

Regional Analysis of Global Hormone Replacement Therapy Industry

Hormone replacement therapy companies are increasingly targeting Canada due to its potential to provide effective and safe treatments for various health conditions.

Canada, along with the US, is expected to dominate the hormone replacement therapy industry, accounting for 24% of the global market. The country's growing elderly population has led to increased healthcare services, and the government is investing in healthcare infrastructure and campaigns to raise public awareness of the benefits of hormone replacement therapy.

Japan is expected to dominate the Asia Pacific region's hormone replacement therapy market by 2030 due to its high senescent population and rising usage of HRT products for osteoporosis, dementia, and other age-related illnesses, making it an attractive market for hormone replacement therapy providers.

Segments Covered in the Hormone Replacement Therapy Market Report

• By Therapy Type:
  • Estrogen Hormone Replacement Therapy
  • Thyroid Replacement Therapy
  • Growth Hormone Replacement Therapy
• By Dosage Form:
  • Tablets
  • Patches
  • Injections
  • Implants
  • Creams
  • Others
• By Indication:
  • Menopause
  • Osteoporosis
  • Thyroid
  • Growth Hormone Deficiency
• By Sales Channel:
  • Hospital Pharmacies
  • Clinics
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Latin America
  • Europe
  • APAC
  • MEA

Frequently Asked Questions

What is the expected growth rate of the Hormone Replacement Therapy market over the next 7 years?

Hormone Replacement Therapy Market is growing with a CAGR of 6.45%, Size, Share, Industry Trends and Forecast to 2030 | Report 2023 by published by Market Report Service.

Who are the major players in the Hormone Replacement Therapy market and what is their market share?

Novo Nordisk A/S, Bayer AG, Endo International Plc, Janssen NV, Mithra Pharmaceuticals, Novartis AG, Pfizer Inc., Allergen Plc, Merck KGaA, Teva Pharmaceuticals, Mylan N.V., are prominent players operating and dominating in the market.

Who are the top 3 Hormone Replacement Therapy Market Key Vendors?

Novo Nordisk A/S, Bayer AG, Endo International Plc, Janssen NV, are key players in the Hormone Replacement Therapy market.

Which geographical areas dominate the worldwide market for Hormone Replacement Therapy?

North America region are emerging as the top regional markets for Hormone Replacement Therapy solutions.